A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Astellas Pharma Inc
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
Amgen
iOnctura
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Inhibrx Biosciences, Inc
Pfizer
RemeGen Co., Ltd.
Shanghai Chest Hospital
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Merck Sharp & Dohme LLC
AstraZeneca
University of Rochester
HC Biopharma Inc.
H. Lee Moffitt Cancer Center and Research Institute
Abramson Cancer Center at Penn Medicine
Cullinan Therapeutics Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Tesaro, Inc.
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
BeiGene
University Health Network, Toronto
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Peking University Cancer Hospital & Institute
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Thomas Jefferson University
Inspirna, Inc.
UNC Lineberger Comprehensive Cancer Center
Boehringer Ingelheim
Blueprint Medicines Corporation
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
GlaxoSmithKline
Arcus Biosciences, Inc.
Genentech, Inc.